MANNKIND CORP Business Acquisition, Pro Forma Earnings Per Share, Diluted
MANNKIND CORP (MNKD) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$0.02 per share for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2023-08-07
- MANNKIND CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2023-06-30 was -$0.02.
- MANNKIND CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2023-03-31 was -$0.04.
- MANNKIND CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2022-09-30 was -$0.05.
- MANNKIND CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2022-06-30 was -$0.11.
- MANNKIND CORP business acquisition, pro forma earnings per share, diluted for fiscal 2022 was -$0.34.
- MANNKIND CORP business acquisition, pro forma earnings per share, diluted for fiscal 2021 was -$0.32.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 6 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 9 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$0.02 10-Q · filed 2023-08-07 | -$0.06 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | -$0.04 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$0.34 10-K · filed 2023-02-23 | |||
| 2022-09-30 | -$0.05 10-Q · filed 2022-11-08 | -$0.27 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | -$0.11 10-Q · filed 2023-08-07 | -$0.22 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$0.10 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$0.32 10-K · filed 2023-02-23 | |||
| 2021-09-30 | -$0.02 10-Q · filed 2022-11-08 | -$0.21 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |